143 patents
Page 6 of 8
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 4 Sep 20
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
ALIREZA REZANIA, REBECA RAMOS-ZAYAS
Filed: 4 Sep 20
Utility
Universal Donor Cells
11 Mar 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Methods and Compositions for Treating Cancer
4 Mar 21
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
Filed: 10 May 19
Utility
Novel Rna-programmable Endonuclease Systems and Uses Thereof
25 Feb 21
Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs).
Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Michael Biag GAMALINDA, Ashish GUPTA, Christian PITZLER, Florian RICHTER, Jan TEBBE, Christopher CHENG, Ryo TAKEUCHI, Caroline W. REISS
Filed: 19 Mar 19
Utility
Self-inactivating (Sin) Crispr/cas or CRISPR/CPF1 Systems and Uses Thereof
4 Feb 21
The invention relates to self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpf1 systems.
Seshidhar Reddy POLICE, Song CHOU, Thomas James CRADICK, Robert NG
Filed: 9 Nov 18
Utility
Methods and Compositions for Improved Homology Directed Repair
14 Jan 21
The disclosure features methods of increasing repair of a DNA double stranded break (DSB) in a target gene by the homology-directed repair (HDR) pathway.
Sanjay D'Souza, Jason West
Filed: 17 Jun 20
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
30 Dec 20
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 2 Aug 20
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
30 Dec 20
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 28 Jul 20
Utility
Materials and Methods for Controlling Gene Editing
30 Dec 20
The present application provides materials and methods for controlling gene editing.
Ryo TAKEUCHI, Abraham SCARIA
Filed: 25 Jun 20
Utility
Gene Editing for Hemophilia a with Improved Factor VIII Expression
9 Dec 20
Provided herein, in some embodiments, are materials and methods for treating hemophilia A in a subject ex vivo or in vivo.
Alan Richard Brooks
Filed: 14 Apr 20
Utility
Materials and Methods for Treatment of Autosomal Dominant Cone-rod Dystrophy
9 Dec 20
The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell.
Ryo TAKEUCHI, Akiko NOMA, Shuying HE, Abraham SCARIA
Filed: 11 Jun 20
Utility
Novel Rna-programmable Endonuclease Systems and Their Use In Genome Editing and Other Applications
9 Dec 20
Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.
Andre COHNEN, Moritz SCHMIDT, Wayne COCO, Ashish GUPTA, Jan TEBBE, Cindy SCHULENBURG, Christian PITZLER, Michael Biag GAMALINDA, Sabine JACH, Florian RICHTER, Anup ARUMUGHAN, Corinna SAALWÄCHTER
Filed: 13 Dec 18
Utility
Materials and Methods for Treatment of Usher Syndrome Type 2A
11 Nov 20
The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell.
Albena KANTARDZHIEVA, Akiko NOMA, Abraham SCARIA
Filed: 17 Jun 20
Utility
Gene-editing Systems for Modifying a SCN9A or SCN10A Gene and Methods of Use Thereof
11 Nov 20
Disclosed herein are highly efficient gene-editing systems for editing a voltage-gated sodium channel gene, such as sodium voltage-gated channel alpha subunit 9 (SCN9A) or sodium voltage-gated channel alpha subunit 10 (SCN10A), either in vitro or in vivo.
Sheena Saayman, Stuart Cahalan, Angela Yen, Sophia Espanola, Sarah Jean Spencer
Filed: 9 Apr 20
Utility
Universal Donor Cells
4 Nov 20
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 13 Jul 20
Utility
Universal Donor Cells
4 Nov 20
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 13 Jul 20
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
21 Oct 20
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 7 Jul 20
Utility
Materials and Methods for Treatment of Hemoglobinopathies
21 Oct 20
Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle l-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglass Borland
Filed: 17 Apr 17
Utility
Materials and Methods for Treatment of Autosomal Dominant Retinitis Pigmentosa
21 Oct 20
The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell.
Albena KANTARDZHIEVA, Akiko NOMA, Abraham SCARIA, Ryo TAKEUCHI
Filed: 1 Apr 20